Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yvette Drew

Showing results (11-20 of 46) with videos related to

Pageof 5
Sort By:
Cancers|April 28, 2017
Targeting the ATR-CHK1 Axis in Cancer TherapyStuart Rundle, Alice Bradbury, Yvette Drew, et al.
Cells|August 12, 2022
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of ResponseAlice Bradbury, Frank T Zenke, Nicola J Curtin, et al.
Cancers|July 26, 2020
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic TargetingAlice Bradbury, Rachel O'Donnell, Yvette Drew, et al.
Cancers|November 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and SchedulingHannah L Smith, Elaine Willmore, Asima Mukhopadhyay, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 2025
Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancerMadeline Rhind, Corinne Maurice-Dror, Yvette Drew, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 28, 2020
Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare NeoplasmHarry Robinson, Manali Karpe, Ibrahim Edidi, et al.
Biochemical Pharmacology|October 21, 2018
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitorsAsima Mukhopadhyay, Yvette Drew, Elizabeth Matheson, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Gynecologic Oncology|December 11, 2025
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewChristina Washington, Bhavana Pothuri, Karen Cadoo, et al.
Cancers|April 3, 2021
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian CancerSweta Sharma Saha, Lucy Gentles, Alice Bradbury, et al.
Pageof 5

Showing results (11-20 of 46) with videos related to

Sort By:
Pageof 5
Cancers|April 28, 2017
Targeting the ATR-CHK1 Axis in Cancer TherapyStuart Rundle, Alice Bradbury, Yvette Drew, et al.
Cells|August 12, 2022
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of ResponseAlice Bradbury, Frank T Zenke, Nicola J Curtin, et al.
Cancers|July 26, 2020
Characterisation of Ovarian Cancer Cell Line NIH-OVCAR3 and Implications of Genomic, Transcriptomic, Proteomic and Functional DNA Damage Response Biomarkers for Therapeutic TargetingAlice Bradbury, Rachel O'Donnell, Yvette Drew, et al.
Cancers|November 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and SchedulingHannah L Smith, Elaine Willmore, Asima Mukhopadhyay, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 1, 2025
Bridging historical evidence and contemporary strategies in the adjuvant treatment of early-stage epithelial ovarian cancerMadeline Rhind, Corinne Maurice-Dror, Yvette Drew, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|January 28, 2020
Enteric Type Bartholin Gland Adenocarcinoma: An Unusual Variant of a Rare NeoplasmHarry Robinson, Manali Karpe, Ibrahim Edidi, et al.
Biochemical Pharmacology|October 21, 2018
Evaluating the potential of kinase inhibitors to suppress DNA repair and sensitise ovarian cancer cells to PARP inhibitorsAsima Mukhopadhyay, Yvette Drew, Elizabeth Matheson, et al.
The Oncologist|October 3, 2019
Real-World Delivery of Rucaparib to Patients with Ovarian Cancer: Recommendations Based on an Integrated Safety Analysis of ARIEL2 and Study 10Yvette Drew, Rebecca S Kristeleit, Ana Oaknin, et al.
Gynecologic Oncology|December 11, 2025
Updates in US Food and Drug Administration approvals for poly-ADP-ribose polymerase inhibitors in Ovarian Cancer: A society of gynecologic oncology clinical practice reviewChristina Washington, Bhavana Pothuri, Karen Cadoo, et al.
Cancers|April 3, 2021
Genomic, Transcriptomic, and Functional Alterations in DNA Damage Response Pathways as Putative Biomarkers of Chemotherapy Response in Ovarian CancerSweta Sharma Saha, Lucy Gentles, Alice Bradbury, et al.
Pageof 5